Below is a comparison chart of some great Aussie Biotechs and...

Below is a comparison chart of some great Aussie Biotechs and their half yearly figures in comparison to market capitalisation. As can be seen Clinuvel is the standout on value when market cap is compared to financial fundamentals. The amazing half yearly results for Clinuvel, were in line with my expectations for full year results of a REVENUE EXPLOSION with more than 50 % full year growth in revenue and profits. This would give Clinuvel approximate full year earnings of $46 - 50 Million Revenue and $21 - $26 Million Profits depending on costs and we know CUV tightly control costs. These sort of amazing figures are broadly in line with Pro Medicus financials which has a market cap over 4 times Clinuvel of about $5 Billion so plenty of upside to the current severe CUV undervaluation. Two things to note are the CUV 2nd half is always much bigger than 1st half, and CUV has a LOT of growth to come with sales only just at the very beginning of access into the US EPP market and sales growth also to come from Australia, Israel and many new markets in Europe.
IMO DYOR